Pages

Saturday, January 21, 2012

Risk Of Cardiac Arrest For Marathon Participants May Be Very Small.

The Wall Street Journal Share to FacebookShare to Twitter (1/12, Hobson, Subscription Publication) reports that new research suggests that the risk of cardiac arrest for those participating in marathons may be very small.
        The Los Angeles Times Share to FacebookShare to Twitter (1/12, Stein) "Booster Shots" blog reports, "Data on about 10 years of marathons and half-marathons in the US were analyzed for the study, released Wednesday in the New England Journal of Medicine." The investigators found that, "out of 10.9 million runners, there were 59 instances of cardiac arrest, 42 of them fatal."
        The AP Share to FacebookShare to Twitter (1/12, Ritter) reports, "The overall figures translate to 1 cardiac arrest per 184,000 participants and one death per 259,000 participants, the researchers said." These "numbers are low compared to other athletic activities, as shown by prior studies of deaths in college athletes, triathlon participants and previously healthy middle-aged joggers, researchers said."
        The CNN Share to FacebookShare to Twitter (1/12, Gardner) "The Chart" blog reports, "The grueling races may be safer than everyday running, in fact. As the study notes, the rate of sudden death among regular joggers has been estimated at one in 7,620 per year."
        The St. Paul Pioneer-Press Share to FacebookShare to Twitter (1/12, Snowbeck) reports that the "The rate of cardiac arrests was higher among men than women, and higher among marathon participants than those running in half-marathon events."
        Bloomberg News Share to FacebookShare to Twitter (1/12, Cortez) reports, "While reports of heart complications and sudden death after long races have risen in recent years, the increase stems from a greater number of participants, the investigators said."
        According to the NPR Share to FacebookShare to Twitter (1/12, Husted) "Shots" blog, one researcher "says that the survivors of race-related cardiac arrests got immediate, bystander-initiated CPR. Among people who died, less than half of got CPR." Also covering the story are WebMD Share to FacebookShare to Twitter (1/12, Doheny), MedPage Today Share to FacebookShare to Twitter (1/12, Fiore), HeartWire Share to FacebookShare to Twitter (1/12, O'Riordan), and HealthDay Share to FacebookShare to Twitter (1/12, Esposito).

Hormone Produced By Exercise May Help Control Obesity, Blood Sugar Levels.

The San Francisco Chronicle Share to FacebookShare to Twitter /Bloomberg News (1/12, Lopatto) reports a study Share to FacebookShare to Twitter in Nature showing that irisin, "a hormone naturally found in muscle cells...rises during exercise, converting white fat into brown fat, a substance whose primary function is to generate body heat." When irisin was injected "into obese, pre-diabetic mice, the animals lost weight and their blood sugar levels improved." Researchers suggested that this finding "may lead to treatments for obesity and diabetes, as well as other disorders where exercise may benefit patients who are too weak to engage in it."
        The New York Times Share to FacebookShare to Twitter (1/12, Reynolds) "Well" blog notes that activity increases the protein "PGC1-alpha, which is produced in abundance in muscles during and after exercise," which then stimulates "the expression of a protein known as Fndc5," which then "[breaks] into different pieces," generating irisin. "Follow-up experiments with muscle cells from human volunteers who'd completed a controlled, weeks-long jogging program found that they had much higher levels of irisin in their cells than before the exercise program began."
        The Boston Globe Share to FacebookShare to Twitter (1/12, Johnson) "White Coat Notes" blog reports, "A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise."
        The UK's Daily Mail Share to FacebookShare to Twitter (1/12) notes, "Those who like a toned physique may still have to make the odd trip to the gym, as irisin does not appear to strengthen muscles." The NPR Share to FacebookShare to Twitter (1/12, Chappell) "The Two Way" blog and the UK's Telegraph Share to FacebookShare to Twitter (1/12, Hough) also cover the story.

Research Challenges Potassium Recommendations For Heart Attack Patients.

HealthDay Share to FacebookShare to Twitter (1/11, Preidt) reports, "Heart attack patients whose blood potassium levels are within a certain range are less likely to die than those with levels of the mineral below or above that range, says a new study Share to FacebookShare to Twitter that challenges current recommendations for potassium levels in heart attack patients." Investigators analyzed data on approximately 39,000 patients admitted to the hospital after experiencing a heart attack. The researchers found that "the death rate for patients with blood potassium levels of between 3.5 and less than 4 mEq/L (milliEquivalents per liter) was 4.8 percent, about the same as the five percent death rate among those with levels of 4 mEq/L to less than 4.5 mEq/L." However, "mortality rose to 10 percent for those with levels of 4.5 to less than 5 mEq/L, and was even higher for those with levels greater than 5 mEq/L, the investigators found." The research was published in the Journal of the American Medical Association.
        HeartWire Share to FacebookShare to Twitter (1/11, Stiles) reports, "While serum K levels of 3.5 to 5.0 mEq/L are considered normal, in acute MI the guidelines recommend potassium administration to maintain a range of 4.0 to 5.0 mEq/L so as to lower the risk of ventricular fibrillation (VF) or cardiac arrest, explained lead author Dr Abhinav Goyal to HeartWire."

Certain Factors May Increase Diabetes Risk.

The UK's Daily Mail Share to FacebookShare to Twitter (1/10, Hagan) reports on "less well-known factors that can increase" the risk of developing type 2 diabetes. These include "carrying a few extra pounds around the waistline," regularly getting "less than five hours' sleep," because "being awake when we should be asleep increases the release of the stress hormone cortisol," having polycystic ovary syndrome (PCOS) due to ovaries producing excess testosterone, "snoring," being pregnant, skipping breakfast, "regularly changing shifts over long periods," and drinking fruit juice instead of "eating whole fruits."

Women Taking Statins May Have Increased Risk Of Type 2 Diabetes.

Broadcast and print media gave wide coverage to a study finding that women taking statins may have an increased risk for type 2 diabetes.
        ABC World News (1/9, story 9, 0:30, Sawyer) reported, "And we have a red flag to tell you about tonight about the most popular prescription drug in the world: statins." Investigators "at Harvard Medical School" found that "people who take statins to reduce their cholesterol are at slightly higher risk of diabetes."
        NBC Nightly News (1/9, story 5, 2:35, Williams) reported that according to the study Share to FacebookShare to Twitter published online Jan. 9 in the Archives of Internal Medicine, "women who take Lipitor [atorvastatin] or other statin drugs for cholesterol have approaching a 50% greater chance of developing diabetes, according to this study," a find that "affects potentially millions of Americans." Chief science correspondent Robert Bazell added, "The study out today from the governments Women's Health Initiative, followed more than 150,000 women over 50 with and without heart disease for about ten years. They found those taking statin drugs had a 48% greater chance of developing type 2 diabetes."
        The Los Angeles Times Share to FacebookShare to Twitter (1/10, Healy) explains, "The heightened risk for diabetes was most pronounced in statin-taking women of Asian origin or those with a body mass index, or BMI, in the healthy range."
        Despite these findings, the "study authors advise patients not to stop taking their medications without talking to a doctor, because statins' proven power to prevent heart attacks and strokes outweighs any potential increase in type 2 diabetes risk," USA Today Share to FacebookShare to Twitter (1/10, Szabo) states.
        The AP Share to FacebookShare to Twitter (1/20, Neergaard) quotes cardiologist Steven Nissen, MD, of the Cleveland Clinic, who said, "What I fear here is that people who need and will benefit from statins will be scared off of using the drugs because of reports like this." Dr. Nissen added, "We don't want these drugs in the water supply, but we want the right people treated. When they are, this effect is not a significant limitation."
        According to HealthDay Share to FacebookShare to Twitter (1/10, Doheny), "When contributing factors such as family history and excess weight were considered, the statin users were nearly 1.5 times more likely to develop diabetes than those not taking statins. The risk applied for all kinds of statin drugs." The study authors "can't explain the link. 'It's still an area under scrutiny,' said" Annie Culver, BPharm, "the study's first author and a consulting pharmacist with the University of Massachusetts Medical School." Culver theorized, "Statins may affect the way the body manages insulin and glucose responses."
        "Culver added that the findings emphasize current guidelines that recommend lifestyle intervention as the primary means of treating high cholesterol," MedPage Today Share to FacebookShare to Twitter (1/10, Fiore) explains. Study author Yunsheng Ma, MD, PhD, of the University of Massachusetts School of Medicine, added, "Too many people are put on a statin who don't have to be." Dr. Ma added, "Patients should go on a statin if they can't control [their cholesterol] through dietary intervention, but once they're on that statin they should still continue lifestyle intervention."
        What's more, WebMD Share to FacebookShare to Twitter (1/10, Boyles) explains that the new "study is not the first to suggest that statins may raise the risk for diabetes." In fact, "an analysis of 13 studies, published in February of 2010, found that statin users had a 9% increased risk for diabetes. Another study, published last June, suggested a similar increase in risk among patients taking high doses of statins." Reuters Share to FacebookShare to Twitter (1/10, Pittman) also covers the story.

Pradaxa Linked to More MIs in Certain Patients

  By Todd Neale, Senior Staff Writer, MedPage Today
Published: January 09, 2012
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

In various patient populations, the anticoagulant dabigatran (Pradaxa) was associated with greater odds of myocardial infarction (MI) or acute coronary syndrome than control treatments, a meta-analysis showed.

Among randomized controlled trials for multiple indications, MI or acute coronary syndrome occurred at a significantly higher rate with dabigatran than with control treatment (1.19% versus 0.79%; OR 1.33, 95% CI 1.03 to 1.71), according to Ken Uchino, MD, and Adrian Hernandez, MD, PhD, of the Cleveland Clinic.

"Clinicians should consider the potential of these serious harmful cardiovascular effects with use of dabigatran," they wrote online in Archives of Internal Medicine.
Action Points  
  • This study evaluated the risk of acute coronary events with the use of dabigatran for several different clinical indications and against different control arms.


  • Dabigatran was associated with an increased risk of myocardial infarction or acute coronary syndrome, but the authors concluded that the risk balance of dabigatran use appears to be favorable in patients with atrial fibrillation because of reduction in ischemic stroke.
In the trials, dabigatran was used for stroke prevention in atrial fibrillation (versus warfarin), prophylaxis for acute venous thromboembolism (versus warfarin) and deep venous thrombosis (versus enoxaparin), and prevention of events in acute coronary syndrome (versus placebo).
"The overall benefit and risk balance of dabigatran use appears to be favorable in patients with atrial fibrillation because of reduction in ischemic stroke," Uchino and Hernandez wrote. "However, the cardiac risk of dabigatran should be investigated further, especially if it is used in populations at high risk of MI or acute coronary syndrome."
In an accompanying editorial, Jeremy Jacobs, MBBS, and Jochanan Stessman, MD, of Hadassah-Hebrew University Medical Center in Jerusalem, wrote, "Uchino and Hernandez suggest that physicians step back for a moment, take their own pulse, and retain a critical view as a powerful new drug enters clinical use on a potentially massive scale."
"The robust finding that dabigatran is associated with increased rates of MI is alarming and emphasizes the need for continued critical appraisal of new drugs after phase III trials," they wrote.
In the largest study of dabigatran -- the 18,000-patient RE-LY trial -- the higher 150-mg dose of the anticoagulant was superior to warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. But there was also a 38% relative increase in the risk of MI (P=0.048).
After an additional search for events, however, the increase was no longer significant (RR 1.27, 95% CI 0.94 to 1.71).
Along the same lines, a recently published post-hoc analysis of the RE-LY trial showed that the risk of MI was not significantly greater with dabigatran than with warfarin, and that the rate of overall major adverse events was significantly lower with the higher dose of dabigatran.
Uchino and Hernandez performed their meta-analysis to further explore the risk of MI or acute coronary syndrome across the patient populations in which dabigatran has been tested. For the purposes of the analysis, patients receiving any dose of dabigatran were grouped together.
The researchers identified seven randomized controlled trials that included 30,514 patients -- two on preventing stroke in atrial fibrillation, one on acute venous thromboembolism prophylaxis, one on preventing events in acute coronary syndrome, and three on short-term prophylaxis of deep venous thrombosis.
The control arms included warfarin, enoxaparin, or placebo.
Although dabigatran use was associated with a significantly higher rate of MI or acute coronary syndrome, the absolute risk increase was small -- 0.27% (95% CI 0.04% to 0.50%).
Using the revised RE-LY results instead of the originally reported results weakened the association, although it maintained borderline statistical significance (OR 1.27, 95% CI 1.00 to 1.61, P=0.05).
Excluding the three short-term trials of dabigatran for prophylaxis of deep venous thrombosis after joint replacement, the higher rate of MI and acute coronary syndrome with the anticoagulant was significant (OR 1.33, 95% CI 1.03 to 1.72).
Uchino and Hernandez noted that they did not know of a pharmacologic mechanism to explain the higher rate of MI or acute coronary syndrome with dabigatran. They said that it could be a factor with dabigatran itself or it could be that the comparator drugs are better at preventing MI.
An important limitation of the meta-analysis is the dominant effect of the RE-LY trial, which included more than 18,000 patients, the researchers said. The largest of the other trials included about 3,500 patients.
In addition, patients were followed for a median of two years in RE-LY, and for six months or less in the other trials.
The study authors and the editorialists reported that they had no conflicts of interest.
From the American Heart Association:


Primary source: Archives of Internal Medicine
Source reference:
Uchino K, Hernandez A "Dabigatran association with higher risk of acute coronary events" Arch Intern Med 2012; DOI: 10.1001/archinternmed.2011.1666.


Additional source: Archives of Internal Medicine
Source reference:
Jacobs J, Stessman J "Dabigatran: do we have sufficient data?" Arch Intern Med 2012. 
 
 
 

BMI May Be Flawed Measure Of Health.

The Boston Globe Share to FacebookShare to Twitter (1/7, Kotz) discussed why body mass index (BMI) may be a limited measure of health, since "some people's weight and height measurements put them in the overweight or even obese category while, in reality, they are very lean and muscular. On the other hand, some people's BMI indicates that they are healthy, when they are actually overfat, with little lean tissue. So, whether or not your BMI indicates that you are overweight, it is important to find out if you are carrying too much body fat." Some experts believe "it's worthwhile to have a body composition test once a year."